Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT01607138
Other study ID # TASMC-12-CTJ-224-CTIL
Secondary ID
Status Not yet recruiting
Phase N/A
First received May 24, 2012
Last updated May 25, 2012
Start date June 2012
Est. completion date December 2014

Study information

Verified date May 2012
Source Tel-Aviv Sourasky Medical Center
Contact Jacob T Cohen, MD
Phone 0524266364
Email jacobc@tasmc.health.gov.il
Is FDA regulated No
Health authority Israel: Ministry of Health
Study type Observational

Clinical Trial Summary

Swallowing and speech difficulties will be observed in patients post laryngectomy. These difficulties will cause decreased in quality of life.


Description:

This study will explore the characteristics of speech and swallowing problems of patients who underwent laryngectomy.The relationship between swallowing disturbances and speech difficulties will be studied and the effect of each problem on quality of life will be messured.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 40
Est. completion date December 2014
Est. primary completion date June 2013
Accepts healthy volunteers No
Gender Both
Age group 35 Years to 80 Years
Eligibility Inclusion Criteria:

- patients post total laryngectomy with voice prothesis

Exclusion Criteria:

- patients who can not read and respod to questions

Study Design

Observational Model: Cohort, Time Perspective: Retrospective


Related Conditions & MeSH terms


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Tel-Aviv Sourasky Medical Center

References & Publications (1)

* Maclean, J., Cotton, S., & Perry, A. (2009). Post-laryngectomy: it's hard to swallow: an Australian study of prevalence and self-reports of swallowing function after a total laryngectomy. Dysphagia, 24(2), 172-179. * Maclean, J., Cotton, S., & Perry, A. (2009). Dysphagia following a total laryngectomy: the effect on quality of life, functioning, and psychological well-being. Dysphagia, 24(3), 314-321. * McHorney, C. A., Robbins, J., Lomax, K., Rosenbek, J. C., Chignell, K., Kramer, A. E., & Bricker, D. E. (2002). The SWAL-QOL and SWAL-CARE outcomes tool for oropharyngeal dysphagia in adults: III. Documentation of reliability and validity. Dysphagia, 17(2), 97-114. * Platteaux, N., Dirix, P., Dejaeger, E., & Nuyts, S. (2010). Dysphagia in head and neck cancer patients treated with chemoradiotherapy. Dysphagia, 25(2), 139-152. * Kapila,M., Deore,N., Palav,R.S., Kazi,R.A., Shah,R.P., & Jagade,M.V.(2011). A brief review of voice restoration following total laryngectomy. Indian Journal of Cancer,48(1),99-104. * Rizzo,B.p.,Maronato,F.,Marchiori,C., Gava,A., &Da Mosto, M,C.(2008). Long-Term Quality of Life After Total Laryngectomy and Postoperative Radiotherapy Versus Concurrent Chemoradiotherapy for Laryngeal Preservation. The Laryngoscope.118,300-306 (2010). Total Laryngectomy.OtorhinolaryngologyMohebati,A. Mohebati,A & * Shah ,p .j , International Journal, 2(3), pp 207-214

Outcome

Type Measure Description Time frame Safety issue
Primary Speech and swallowing characteristics of patients post laryngectomy After recording the patients' speech the speech characteristics will be analysed according to specific parameters. Also after performing swallowing eveluation swallowing disturbances will be diagnosed and described. At the completion of data collection -1 year No
Secondary The relationship between speech and swallowing disturbances of patients post laryngectomy After analyzing the speech and swallowing disturbances of patients post laryngectomy, the relationship between these variables will be examined. 1 year at the completion of data collection No
See also
  Status Clinical Trial Phase
Completed NCT00117572 - Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE) Phase 3
Recruiting NCT00970502 - Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer Phase 1/Phase 2
Completed NCT00462735 - Fluorouracil, Hydroxyurea, Cetuximab and Twice-daily Intensity Radiation Therapy for Advanced Head and Neck Cancer Phase 2
Active, not recruiting NCT00593840 - Phase II Trial Evaluating Elimination of Radiation Therapy Phase 2